LPX TI641
Alternative Names: LPX-TI-641Latest Information Update: 02 Jan 2026
At a glance
- Originator LAPIX Therapeutics
- Class Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules
- Mechanism of Action Immune checkpoint protein stimulants; Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis; Multiple sclerosis; Myelin oligodendrocyte glycoprotein antibody-associated disease; Neuromyelitis optica; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 15 Jun 2025 Phase-I clinical trials in Atopic dermatitis (Treatment-experienced) in Jordan, USA (PO) (NCT06982352)
- 15 Jun 2025 Phase-I clinical trials in Psoriasis (Treatment-experienced) in Jordan, USA (PO) (NCT06982352)
- 21 May 2025 LAPIX Therapeutics plans a phase Ib trial for Atopic dermatitis (Treatment experienced)and Psoriasis in June 2025 (PO) (NCT06982352)